Pressroom
Update: An IND Is Not Required for FMT
Fecal microbiota transplant (FMT) is a promising treatment for Clostridium difficile. Reversing previous guidance, the FDA will not require an investigational new drug application (IND) for the use of FMT to treat C. difficile infection not responding to standard therapies. This great news for patients came after AGA worked very closely with FDA on this issue and issued a public statement calling on the agency to streamline the process of getting FMT to patients in need.
Screening At-Risk Adolescents for Celiac Disease Proves Cost-Effective and Successful in Preventing Bone Disease
The current standard practice of screening adolescents who are either symptomatic or at high-risk for celiac disease proves to be more cost-effective than universal screening, according to a new study in Clinical Gastroenterology and Hepatology.
NYT Editorial Board Addresses Colonoscopy
AGA Institute Journal Embargo Policy
When a manuscript is accepted for publication in either Gastroenterology or Clinical Gastroenterology and Hepatology, it is under embargo and not for public release until publication. Articles are typically embargoed until 3 p.m. ET the day of online publication.
Authors are permitted to present their research prior to publication before peers at scientific meetings, but should refrain from distributing copies of their paper, including data tables and figures.
View the AGA’s embargo policy for Gastroenterology and Clinical Gastroenterology and Hepatology.
AGA News Release Archives
Patient Education Materials
To help you understand and manage your digestive health condition or to prepare for your procedure, the AGA Institute provides patients with educational information, designed to give you some basic facts and to serve as a starting point for discussions with your doctor.
Probiotics: What They Are and What They Can Do for You
Contact Us
Aimee Frank
AGA Director of Public Relations
(301) 941-2620
media@gastro.org
